Why telehealth is winning the distribution war.

In January 2024, Eli Lilly opened a website that sold Lilly's own products to patients without a pharmacy benefit manager anywhere in the transaction. In March 2025, Novo Nordisk did essentially the same thing. The distribution war for GLP-1s was not won by telehealth companies out-competing the pharmacy counter. It was conceded — by the two manufacturers who decided the insurance channel was no longer worth defending for obesity.

Here is the thesis. Telehealth dominates GLP-1 distribution not because virtual care is clinically superior, and not because it is cheaper, but because obesity pharmacotherapy became a cash-pay category — and telehealth is the only distribution infrastructure in American medicine that was designed for cash-pay from the first day. Everyone else has to retrofit.

Most coverage of this gets the causality backwards. It reads the rise of direct-to-consumer prescribing as a story about consumer preference, or convenience, or the erosion of the doctor-patient relationship. I think it is much simpler and much more structural than that: the payment method changed, and distribution followed the payment method, as it always does.

The minimum background. For a normal branded drug, the path runs prescriber to pharmacy benefit manager to retail pharmacy, with a prior authorization somewhere in the middle and a rebate negotiated out of view. Obesity drugs failed at nearly every step of that path. Medicare has been statutorily barred from covering drugs used for weight loss since 2003. Employer plans that did cover them started walking it back as spend compounded. State Medicaid programs began dropping coverage outright — North Carolina's state health plan ended GLP-1 coverage for weight loss in 2024, West Virginia's public employee program did the same. A channel that cannot reliably deliver the product is not a channel.

The manufacturers chose the channel themselves

LillyDirect launched in January 2024. By 2025 it was selling single-dose Zepbound vials on a self-pay basis at roughly $349 to $499 a month depending on strength, a price set by the manufacturer and paid by credit card. NovoCare Pharmacy followed in March 2025, offering all Wegovy doses to cash-paying patients at about $499 a month.

Read what that actually is. Two of the largest pharmaceutical companies on earth built retail storefronts, priced their own products against themselves, and routed the prescription requirement through contracted telehealth platforms. They did not partner with telehealth as a marketing experiment. They made telehealth the front door.

That is the whole war in one sentence. When the manufacturer publishes a cash price and points you at a virtual prescriber, the pharmacy counter is not losing a competition. It has been removed from the diagram.

Cash-pay medicine needed a machine that already existed

Here is the piece I think is genuinely underrated. GLP-1 therapy for weight management has a shape that maps almost perfectly onto direct-to-consumer software: a monthly refill, a titration schedule that produces predictable follow-up contact, an indefinite duration, and a patient population that is highly motivated and comfortable transacting online.

That is a subscription business wearing a lab coat. Hims & Hers, the clearest case, reported roughly $1.48 billion in 2024 revenue, up about 69% year over year, with weight management as the engine of that growth. LifeMD, Ro, and Noom built or expanded comparable programs in the same window. None of these companies invented anything clinical. They already had the billing, the recurring-charge mechanics, the asynchronous intake, and the shipping.

A retail pharmacy has none of that. It has an adjudication system built to talk to insurers, staff time budgeted around fills rather than around monthly check-ins, and no mechanism for the recurring relationship the category requires. Asking CVS to compete for a $499 cash subscription is asking a bank branch to compete with a payments API.

Meanwhile the incumbents of the old weight-loss economy discovered they were in the wrong business entirely. WeightWatchers — the company that essentially defined commercial weight management for six decades — filed for Chapter 11 bankruptcy protection in May 2025. Its assets were behavioral. The category had gone pharmacological, and the distribution rents moved with it.

The Hims rupture showed who actually holds power

The most instructive event of the last two years was also the most public failure. On April 29, 2025, Novo Nordisk announced a distribution partnership putting Wegovy through Hims & Hers. On June 23, 2025 — under two months later — Novo terminated it, publicly accusing the platform of continuing to sell knockoff compounded semaglutide and of "deceptive marketing." The stock fell roughly a third in a day.

I think that episode is the single best correction to the triumphalist read of telehealth. These platforms won distribution, which is real. They did not win supply, which is the thing that actually matters. Every dollar of branded GLP-1 revenue running through a virtual clinic exists at the pleasure of a manufacturer that can terminate the arrangement by press release on a Monday morning.

That is a rented position, not an owned one. It is why the same platforms have spent the period since diversifying into anything with a molecule and a monthly cadence — and why the compounding wind-down after the FDA declared the semaglutide shortage resolved in February 2025, with 503A pharmacies given until April 22 and 503B outsourcing facilities until May 22, hit the sector as hard as it did.

The insurance channel lost by being itself

The cash channel did not have to win an argument. The insurance channel kept making it for them.

The clearest example: effective July 1, 2025, CVS Caremark made Wegovy the preferred GLP-1 on its standard commercial template formulary and excluded Zepbound. Set aside which drug you think should have won. In SURMOUNT-5, the head-to-head, tirzepatide produced roughly 20.2% mean weight loss against semaglutide's 13.7%. A formulary decision moved a large population off the arm that had won the trial, for reasons that were commercial rather than clinical.

You cannot design a better advertisement for paying cash. Every prior authorization denial, every mid-year formulary switch, every employer carve-out is a lead generation event for a channel whose entire pitch is this will not happen to you here. The insurance system's own volatility has been the direct-pay channel's most effective marketing, and it did not cost the platforms a cent.

Let me be explicit about what this essay is not. This is market and channel analysis. Ozemback does not recommend, rank, or refer anyone to any pharmacy, platform, clinic, or prescriber, and nothing here is guidance about any individual's care — that belongs to a person and their licensed clinician. The subject here is where money and molecules move, which is a different question entirely.

The strongest case that I am wrong

Take the counter-argument seriously. It has three parts, and the first is the strongest.

One: winning distribution is not the same as delivering care, and the persistence data are not flattering. Real-world claims analyses have repeatedly found that a majority of people prescribed a GLP-1 for weight management are no longer filling it a year later; some analyses of commercial claims put discontinuation well above half within the first twelve months. If a channel is excellent at acquisition and mediocre at retention, calling it the winner may just mean it is the best at the easy half of the problem.

Two: the position is rented, as the Hims termination demonstrated in the crudest possible terms. A channel that can be revoked is a channel with a landlord.

Three, and most consequential: orforglipron. An orally administered small-molecule GLP-1 requires no cold chain, no injection training, no specialty handling, and can be manufactured at a scale injectable peptides cannot approach. If a daily oral agent reaches the market at a price that works inside a normal pharmacy benefit, the strongest structural advantage telehealth has — being the only convenient route to an expensive, refrigerated, self-injected product — weakens considerably. Retail pharmacy is extremely good at dispensing pills.

I find the third argument the most serious and I still think it changes the timeline rather than the outcome. Distribution habits, once formed, are sticky in a way pricing is not. A patient who has spent two years receiving medication by subscription, with intake by questionnaire and follow-up by message, does not return to a waiting room because a pill became available. The channel was built during the injectable era; it will not be dismantled by the oral one.

What the win actually was

So here is the plain version. Telehealth is winning the GLP-1 distribution war because obesity medicine detached from insurance faster than any major drug category in modern American history, and the direct-pay world had a working delivery system sitting there when it happened.

The manufacturers ratified the shift rather than resisting it, which is the part that ought to unsettle people more than it does. LillyDirect and NovoCare are not experiments at the edge of the business. They are two of the largest drugmakers in the world concluding that, for this category, they would rather sell to patients than negotiate with payers.

The most underrated consequence is not convenience. It is that a category of chronic medication — one intended to be taken for years, in a population with real cardiometabolic risk — has quietly relocated to the part of the healthcare system with the least continuity, the thinnest longitudinal record, and no obligation to anyone once the card declines. That is the trade the market made. It is worth naming it as a trade rather than a triumph.

Ozemback — July 2026